Money
Filter News
Found 83,198 articles
-
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
1/2/2024
Aditxt, Inc. announced that it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550, subject to a mandatory panel monitor until December 29, 2024.
-
CardioMech Raises $13m in Heavily Oversubscribed Round for Its Transcatheter Mitral Chordal Repair Technology
1/2/2024
Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, announced it has closed on $13M in fresh capital.
-
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
1/2/2024
MannKind Corporation announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.
-
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
1/2/2024
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.
-
Aptar Announces 2024 Quarterly Conference Call Dates
1/2/2024
AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, announced the dates and times of quarterly conference calls for the year.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
Zentalis® Pharmaceuticals, Inc. announced that on January 2, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 6,250 shares of the Company’s common stock to two newly hired employees.
-
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
1/2/2024
Journey Medical Corporation announced that the Company has entered into a credit facility with an affiliate of SWK Holdings Corporation, a specialized finance company with a focus on the global healthcare sector, providing for borrowings of up to $20 million.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 29, 2023, as inducements material to such employee entering into employment with Akebia.
-
Cloud DX Announces Closing of $1,942,000 Private Placement of Convertible Debenture Units, Amendments to Existing Secured Convertible Securities, and Equity Incentive Grants
1/2/2024
Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) ("Cloud DX" or the "Company"), is pleased to announce that, further to the Company's news release dated December 7, 2023, it has closed its previously announced non-brokered private
-
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split - Jan 02, 2024
1/2/2024
SAB Biotherapeutics, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on January 5, 2024.
-
Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million
1/2/2024
Apollo Therapeutics announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.
-
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock - Jan 02, 2024
1/2/2024
Longboard Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $150 million of shares of its voting common stock.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted 42,000 restricted stock units to one newly-hired employee.
-
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
1/2/2024
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers
-
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
1/2/2024
Bluejay Diagnostics, Inc. announced the closing of its previously announced public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.
-
BioHarvest Sciences Inc. Closes Final Tranche of Oversubscribed $13.5M Private Placement
1/2/2024
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or the "Company") is pleased to announce that it has closed the second and final tranche of its non-brokered private placement of convertible notes
-
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
12/29/2023
MiMedx Group, Inc. provided the following update regarding AXIOFILL and reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA margin.
-
PharmAla Files Audited Financials for Year Ending August 31, 2023
12/29/2023
PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules, is pleased to file its audited financial statements for the year ended on August 31, 2023.
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - December 29, 2023
12/29/2023
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted an inducement award on December 29, 2023.